Immediate sell pressure expected from the massive share overhang. Watch for a possible price gap down on opening as the new shares hit the market. The extended cash runway into mid-2028 is a positive for the NXC-201 pipeline, but the dilution magnitude will dominate near-term price action. Monitor for any secondary offering or warrant registration cascade in the coming weeks.
Price Chart
Executive Summary
Immix Biopharma priced an underwritten offering of 16,778,524 shares at $8.94 per share, raising $150M in gross proceeds (~$140.65M net). This massively dilutive event increases shares outstanding by roughly 31% (based on a ~$486M market cap at $20.57 pre-offering, implying ~23.6M shares pre-offering). Proceeds will fund NXC-201 CAR-T development and extend cash runway into mid-2028.
Key Facts
- 16,778,524 shares offered at $8.94 per share for gross proceeds of $150M
- Net proceeds estimated at ~$140.65M after underwriting discounts and expenses
- Underwriters include Morgan Stanley (lead), BofA, LifeSci Capital, Mizuho, Needham
- Shares sold at $8.4036 per share to underwriters (6% discount from public price)
- 90-day lock-up agreements on officers and directors
- Proceeds to fund NXC-201 CAR-T development and extend cash runway into mid-2028
- Net dilution of ~31% to existing shareholders based on share count implied by market cap
Financial Impact
$150M gross / ~$140.65M net proceeds raised via 16.78M share offering at $8.94/share; dilution ~31% to pre-offering float
Risk Factors
- Immediate dilution of ~31% will pressure stock price
- Potential for follow-on offerings as shelf registration remains available
- Clinical trial risk for NXC-201 could be amplified given larger share base
- Underwriters may have overallotment option (not specified but typical) adding further dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024872 |
| Exhibit: ex5-1.htm | 0001493152-26-024872 |
| Exhibit: ex99-1.htm | 0001493152-26-024872 |
| Document: form8-k.htm | 0001493152-26-024872 |
| Document: 0001493152-26-024872-index-headers.html | 0001493152-26-024872 |
| Document: 0001493152-26-024872-index.html | 0001493152-26-024872 |
| Document: 0001493152-26-024872.txt | 0001493152-26-024872 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $10.23 $9.29 | ▲ +9.19% | ▲ +10.49% | $8.15 (+20.33%) |
Sep 29, 2026 27d ago | 424B5 | $10.54 $9.64 | ▲ +8.54% | ▲ +10.49% | $8.15 (+22.68%) |
Sep 29, 2026 27d ago | 8-K | $10.54 $9.64 | ▼ −8.54% | ▼ −10.49% | $8.15 (−22.68%) |
Jul 20, 2026 14w ago | 8-K | $8.80 $8.52 | ▼ −3.18% | ▼ −2.76% | $8.15 (−7.39%) |
May 21, 2026 22w ago | 8-K | $8.78 $9.22 | ▼ −5.01% | ▼ −3.35% | $8.15 (+7.18%) |
May 21, 2026 22w ago | Press Release | $8.67 $9.00 | ▲ +3.81% | ▲ +1.96% | $8.15 (−6.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers